Pieris Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.3049
- Today's High:
- $0.33
- Open Price:
- $0.315
- 52W Low:
- $0.162
- 52W High:
- $1.97
- Prev. Close:
- $0.316
- Volume:
- 876424
Company Statistics
- Market Cap.:
- $31.23 million
- Book Value:
- 0.41
- Revenue TTM:
- $33.21 million
- Operating Margin TTM:
- -111.83%
- Gross Profit TTM:
- $-27080000
- Profit Margin:
- -81.44%
- Return on Assets TTM:
- -23%
- Return on Equity TTM:
- -63.74%
Company Profile
Pieris Pharmaceuticals Inc had its IPO on 2015-04-13 under the ticker symbol PIRS.
The company operates in the Healthcare sector and Biotechnology industry. Pieris Pharmaceuticals Inc has a staff strength of 127 employees.
Stock update
Shares of Pieris Pharmaceuticals Inc opened at $0.32 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.3 - $0.33, and closed at $0.33.
This is a +3.23% increase from the previous day's closing price.
A total volume of 876,424 shares were traded at the close of the day’s session.
In the last one week, shares of Pieris Pharmaceuticals Inc have slipped by -5.72%.
Pieris Pharmaceuticals Inc's Key Ratios
Pieris Pharmaceuticals Inc has a market cap of $31.23 million, indicating a price to book ratio of 2.0801 and a price to sales ratio of 2.5965.
In the last 12-months Pieris Pharmaceuticals Inc’s revenue was $33.21 million with a gross profit of $-27080000 and an EBITDA of $-34430000. The EBITDA ratio measures Pieris Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pieris Pharmaceuticals Inc’s operating margin was -111.83% while its return on assets stood at -23% with a return of equity of -63.74%.
In Q2, Pieris Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 442.3%.
Pieris Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pieris Pharmaceuticals Inc’s profitability.
Pieris Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.5892 and a EV to EBITDA ratio of -0.4897. Its price to sales ratio in the trailing 12-months stood at 2.5965.
Pieris Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $87.54 million
- Total Liabilities
- $34.37 million
- Operating Cash Flow
- $-1366000.00
- Capital Expenditure
- $67000
- Dividend Payout Ratio
- 0%
Pieris Pharmaceuticals Inc ended 2024 with $87.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $87.54 million while shareholder equity stood at $40.50 million.
Pieris Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $34.37 million in other current liabilities, 99000.00 in common stock, $-299628000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $44.94 million and cash and short-term investments were $54.88 million. The company’s total short-term debt was $910,000 while long-term debt stood at $0.
Pieris Pharmaceuticals Inc’s total current assets stands at $66.47 million while long-term investments were $0 and short-term investments were $9.94 million. Its net receivables were $952000.00 compared to accounts payable of $9.14 million and inventory worth $0.
In 2024, Pieris Pharmaceuticals Inc's operating cash flow was $-1366000.00 while its capital expenditure stood at $67000.
Comparatively, Pieris Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.33
- 52-Week High
- $1.97
- 52-Week Low
- $0.162
- Analyst Target Price
- $7
Pieris Pharmaceuticals Inc stock is currently trading at $0.33 per share. It touched a 52-week high of $1.97 and a 52-week low of $1.97. Analysts tracking the stock have a 12-month average target price of $7.
Its 50-day moving average was $0.26 and 200-day moving average was $0.87 The short ratio stood at 0.26 indicating a short percent outstanding of 0%.
Around 1498.5% of the company’s stock are held by insiders while 6791.7% are held by institutions.
Frequently Asked Questions About Pieris Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.